Add to ORKGprotease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus Conclusions: The incidence and persistence of protease resistance mutations occurring in HCV from chronically Hoffmann et al. Virology Journal 2013, 10:5
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
(See the editorial commentary by Fanning, on pages 797–9.) Background. The prevalence and clinical i...
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which i...
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
Background and objective: Presently, it has been approved to treat hepatitis C virus (HCV) infection...
Background: Direct-acting antivirals (DAAs) are predicted to transform hepatitis C therapy, yet litt...
The aim of this study was to measure the frequency of natural mutations in hepatitis C virus (HCV) m...
Direct-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C vi...
Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million ...
AbstractDirect-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepati...
Several new direct-acting antiviral (DAA) drugs are in development for chronic hepatitis C viral (HC...
Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved ...
Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Br...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
(See the editorial commentary by Fanning, on pages 797–9.) Background. The prevalence and clinical i...
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which i...
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
Background and objective: Presently, it has been approved to treat hepatitis C virus (HCV) infection...
Background: Direct-acting antivirals (DAAs) are predicted to transform hepatitis C therapy, yet litt...
The aim of this study was to measure the frequency of natural mutations in hepatitis C virus (HCV) m...
Direct-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C vi...
Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million ...
AbstractDirect-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepati...
Several new direct-acting antiviral (DAA) drugs are in development for chronic hepatitis C viral (HC...
Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved ...
Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Br...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
(See the editorial commentary by Fanning, on pages 797–9.) Background. The prevalence and clinical i...